abivertinib

Abivertinib is a third-generation, irreversible, orally available small molecule tyrosine kinase inhibitor that selectively targets mutant forms of the epidermal growth factor receptor (EGFR), including the T790M resistance mutation, and also inhibits Bruton's tyrosine kinase (BTK). It is designed to overcome acquired resistance to first-generation EGFR inhibitors in non-small cell lung cancer (NSCLC) and has minimal activity against wild-type EGFR. Abivertinib also exerts immunomodulatory effects by inhibiting BTK, which impacts B-cell proliferation and survival as well as immune regulation. The drug has been investigated for NSCLC with EGFR mutations resistant to prior therapy, B-cell malignancies such as marginal zone lymphoma, prostate cancer, and was previously studied for COVID‑19 due to its ability to suppress cytokine release[1][2][3][4][5].

Brand names

FUJOVEE

Other names

abivertinib maleateavitinib (superceded INN)